Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 265

Sort by

Sort Order Select

Journal Articles

End points and outcomes in follicular lymphoma: what should we measure, how, and why?

Mengyang Di, Matthew J. Maurer, Christopher R. Flowers

Blood (2025) 146 (15): 1802–1811.

https://doi.org/10.1182/blood.2024026978

Published: 2025

Journal Articles

PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study

Blood blood.2025028848.

https://doi.org/10.1182/blood.2025028848

Published: 2025

Journal Articles

Blunted CD40-responsive enhancer activation in CREBBP -mutant lymphomas can be restored by enforced CD4 T-cell engagement

Blood (2025) 146 (2): 191–205.

https://doi.org/10.1182/blood.2024026664

Published: 2025

Includes: Supplemental data

Journal Articles

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy

Blood (2025) 145 (8): 823–839.

https://doi.org/10.1182/blood.2024025366

Published: 2025

Includes: Supplemental data

Journal Articles

Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis

Blood (2024) 144 (19): 2063–2066.

https://doi.org/10.1182/blood.2024025681

Published: 2024

Includes: Supplemental data

Journal Articles

T-Cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis Has Worse Survival When Compared to T-Cell Lymphoma: A Retrospective Analysis from a Single Tertiary Center

Blood (2024) 144 (Supplement 1): 6420.

https://doi.org/10.1182/blood-2024-211482

Published: 2024

Journal Articles

Phase II Trial of Axicabagene Ciloleucel and Glofitamab As Second-Line Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma

Kunhwa Kim, Dai Chihara, Luis E. Fayad, Sattva S. Neelapu, Sairah Ahmed, Frederick Hagemeister, Chijioke Nze, Swaminathan P Iyer, Preetesh Jain, Michael Wang, Paolo Strati, Fateeha Furqan, Ayushi Chauhan, Michael R. Green, Christopher R. Flowers, Jason R. Westin

Blood (2024) 144 (Supplement 1): 4511.1.

https://doi.org/10.1182/blood-2024-205196

Published: 2024

Journal Articles

Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3038.

https://doi.org/10.1182/blood-2024-206042

Published: 2024

Journal Articles

Interim PET-Adapted De-Escalation Chemotherapy Regimen for Advanced Stage Classical Hodgkin Lymphoma Using Brentuximab Vedotin, Pembrolizumab, Doxorubicin, and Dacarbazine: Phase 2 Safety and Efficacy Study

Hun Ju Lee, Gregory Ravizzini, Eslam Aboismail, Jenna Wixom, Jared Henderson, Luis E. Fayad, Sairah Ahmed, Ranjit Nair, Jason R. Westin, Swaminathan P Iyer, Chijioke Nze, Ajlan Al Zaki, Francisco Vega, Michael Wang, Christopher R. Flowers, Luis Malpica

Blood (2024) 144 (Supplement 1): 1674.3.

https://doi.org/10.1182/blood-2024-212005

Published: 2024

Journal Articles

An Economic Analysis Assessing the Budget Impact of Introducing Glofitamab with Gemcitabine and Oxaliplatin for Autologous Stem Cell Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma to a United States Health Plan

David Fox, Katherine L Rosettie, Fadoua El Moustaid, Anthony Masaquel, Lourenia Cassoli, Christopher R. Flowers

Blood (2024) 144 (Supplement 1): 3646.

https://doi.org/10.1182/blood-2024-198451

Published: 2024

Journal Articles

Retreatment with R-CHOP-like Therapy Is Active with Durable Responses in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma

Eduardo Edelman Saul, Bryan Valcarcel, Amy A. Ayers, Mansoor Noorani, Dai Chihara, Fateeha Furqan, Sairah Ahmed, Swaminathan P Iyer, Sattva S. Neelapu, Luis E. Fayad, F. B. Hagemeister, Chijioke Nze, Preetesh Jain, Michael Wang, Paolo Strati, Ayushi Chauhan, Francisco Vega, Christopher R. Flowers, Jason R. Westin

Blood (2024) 144 (Supplement 1): 4454.

https://doi.org/10.1182/blood-2024-211247

Published: 2024

Journal Articles

Radiation Therapy and Monocyte Activation in Large B-Cell Lymphoma Patients Treated with CAR T-Cell Therapy

Blood (2024) 144 (Supplement 1): 4377.

https://doi.org/10.1182/blood-2024-203844

Published: 2024

Journal Articles

Treatment Patterns and Real World Outcomes with Clinical Trials for Patients with Follicular Lymphoma across Lines of Therapy

Neha Akkad, Amy Ayers, Kumudha Balakrishnan, Loretta Nastoupil, Dai Chihara, Luis Malpica, Paolo Strati, Ziyi Li, Christopher R. Flowers

Blood (2024) 144 (Supplement 1): 4396.

https://doi.org/10.1182/blood-2024-201804

Published: 2024

Journal Articles

Clinical Outcomes and Patterns of Care Among Patients with Newly Diagnosed Hodgkin Lymphoma in a Safety-Net Health System

Jun Yang Jiang, Trung Minh Nguyen, Jason Lu, Danielle Guffey, Rockbum Kim, Abiodun Oluyomi, Omar Rosales, Raka Bandyo, Courtney Nicole Miller-Chism, Mark M. Udden, Martha P. Mims, Tareq Abuasab, Akiva Diamond, Purnima Sravanti Teegavarapu, Chijioke Nze, Christopher R. Flowers, Ang Li

Blood (2024) 144 (Supplement 1): 3727.

https://doi.org/10.1182/blood-2024-203368

Published: 2024

Journal Articles

Peripheral Blood CAR T-Cell Level Using a Clia-Validated Assay Is Prognostic for Treatment Response and Icans in Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3001.

https://doi.org/10.1182/blood-2024-208300

Published: 2024

Journal Articles

Real-World Predictors of Financial Toxicity in Patients with Lymphoma

Blood (2024) 144 (Supplement 1): 3754.

https://doi.org/10.1182/blood-2024-201896

Published: 2024

Journal Articles

Collective Analysis of Genomic Data Sets to Assess the Impact of Eligibility Criteria on Molecular Subsets in First-Line Clinical Trials for Patients with Diffuse Large B-Cell Lymphoma

Robert Andrew Harkins, Dai Chihara, Christopher R. Flowers

Blood (2024) 144 (Supplement 1): 2970.

https://doi.org/10.1182/blood-2024-198813

Published: 2024

Journal Articles

Comprehensive Molecular Characterization of Monomorphic Post-Transplant Lymphoproliferative Disorder (PTLD)

Jean L. Koff, Kumudha Balakrishnan, Michael Churnetski, Michelle J. Lee, Anna Kurilovich, Svetlana Paponova, Alexander Nesmelov, Ksenia Zornikova, Pavel Zemskiy, Alexander Bagaev, Nikita Kotlov, Christopher R. Flowers

Blood (2024) 144 (Supplement 1): 5759.

https://doi.org/10.1182/blood-2024-209996

Published: 2024

Journal Articles

Tumor Genomics and Microenvironment Characterization of Diffuse Large B-Cell Lymphoma in Asian and Pacific Islander Patients

Michelle J. Lee, Kumudha Balakrishnan, Pavel Zemskiy, James D. Ayres, Timothy J. McDonnell, Neha Akkad, Kiril Kriukov, Arina Tkachuk, Ksenia Zornikova, Krystle Nomie, Aleksander Bagaev, Jean L. Koff, Christopher R. Flowers

Blood (2024) 144 (Supplement 1): 6209.

https://doi.org/10.1182/blood-2024-210739

Published: 2024

Journal Articles

Utilizing Synthetic Individual Patient Level Cohorts from Machine Learning on Clinical Trials to Define Endpoints for Bispecific Trials in Large B-Cell Lymphoma

Dai Chihara, Micheal J. Kane, Christopher R. Flowers, Brian P. Hobbs

Blood (2024) 144 (Supplement 1): 4462.

https://doi.org/10.1182/blood-2024-193578

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

End points and outcomes in follicular lymphoma: what should we measure, how, and why?

PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study

Blunted CD40-responsive enhancer activation in CREBBP -mutant lymphomas can be restored by enforced CD4 T-cell engagement

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy

Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis

T-Cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis Has Worse Survival When Compared to T-Cell Lymphoma: A Retrospective Analysis from a Single Tertiary Center

Phase II Trial of Axicabagene Ciloleucel and Glofitamab As Second-Line Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma

Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma

Interim PET-Adapted De-Escalation Chemotherapy Regimen for Advanced Stage Classical Hodgkin Lymphoma Using Brentuximab Vedotin, Pembrolizumab, Doxorubicin, and Dacarbazine: Phase 2 Safety and Efficacy Study

An Economic Analysis Assessing the Budget Impact of Introducing Glofitamab with Gemcitabine and Oxaliplatin for Autologous Stem Cell Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma to a United States Health Plan

Retreatment with R-CHOP-like Therapy Is Active with Durable Responses in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma

Radiation Therapy and Monocyte Activation in Large B-Cell Lymphoma Patients Treated with CAR T-Cell Therapy

Treatment Patterns and Real World Outcomes with Clinical Trials for Patients with Follicular Lymphoma across Lines of Therapy

Clinical Outcomes and Patterns of Care Among Patients with Newly Diagnosed Hodgkin Lymphoma in a Safety-Net Health System

Peripheral Blood CAR T-Cell Level Using a Clia-Validated Assay Is Prognostic for Treatment Response and Icans in Large B-Cell Lymphoma

Real-World Predictors of Financial Toxicity in Patients with Lymphoma

Collective Analysis of Genomic Data Sets to Assess the Impact of Eligibility Criteria on Molecular Subsets in First-Line Clinical Trials for Patients with Diffuse Large B-Cell Lymphoma

Comprehensive Molecular Characterization of Monomorphic Post-Transplant Lymphoproliferative Disorder (PTLD)

Tumor Genomics and Microenvironment Characterization of Diffuse Large B-Cell Lymphoma in Asian and Pacific Islander Patients

Utilizing Synthetic Individual Patient Level Cohorts from Machine Learning on Clinical Trials to Define Endpoints for Bispecific Trials in Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only